Praxis Precision (NASDAQ: PRAX) officer reports tax withholding shares

Rhea-AI Filing Summary

Praxis Precision Medicines, Inc. reported an insider equity transaction by its Principal Accounting Officer, Lauren Mastrocola. On January 7, 2026, 35 shares of Praxis common stock were withheld by the company at a price of $292.63 per share to cover tax obligations tied to the vesting of previously reported restricted stock units. After this tax withholding, Mastrocola beneficially owns 10,406.656 shares of Praxis common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mastrocola Lauren

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/07/2026		F(1)		35	D	$292.63	10,406.656	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported restricted stock units.

Remarks:

	/s/ Alex Nemiroff, as Attorney-in-Fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Praxis Precision Medicines (PRAX) report on January 7, 2026?

The company reported that Principal Accounting Officer Lauren Mastrocola had 35 shares of Praxis common stock withheld on January 7, 2026 at $292.63 per share to satisfy tax withholding obligations related to vesting restricted stock units.

Who is the reporting person in this Praxis Precision Medicines (PRAX) Form 4?

The reporting person is Lauren Mastrocola, who serves as Principal Accounting Officer of Praxis Precision Medicines, Inc.

Was the Praxis (PRAX) insider transaction an open-market sale?

No. The Form 4 explains that the 35 shares were withheld by the issuer to satisfy tax withholding obligations arising from the vesting of previously reported restricted stock units, rather than sold in an open-market trade.

How many Praxis (PRAX) shares does the insider beneficially own after this transaction?

Following the reported tax withholding transaction, Principal Accounting Officer Lauren Mastrocola beneficially owns 10,406.656 shares of Praxis common stock directly.

Does this Praxis (PRAX) Form 4 show the insider as a 10% owner?

No. The Form 4 indicates that Lauren Mastrocola is an officer (Principal Accounting Officer) and not a 10% owner of Praxis Precision Medicines, Inc.

What is the transaction code used in this Praxis (PRAX) Form 4 filing and what does it signify?

The transaction uses code F, which in this context is associated with shares withheld by the issuer to cover tax obligations when restricted stock units vest.